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Fluorescence labeled small interfering RNAs (siRNAs) were loaded into lipopolyplexes
modified with ApoA1 (named as rHDL) and administered by intravenous injection. The
biodistribution with time of these lipopolyplexes inside the liver and among various cell
types was followed using tissue sections by Confocal fluorescence microscopy. At about
0.5 h after tail vein injection at a dose of 0.408 mg/kg, very few fluorescence signals were
found in the liver. But then the signals could be seen to accumulate inside hepatocytes as
discrete spots and diffused signals at around 2e4 h after injection. Such a distribution and
uptake pattern was significantly different from what were observed using the commercial
agent Invivofectamine 2.0 or DOTAP lipoplexes as the carriers. The differences indicated
different mechanisms concerning the in vivo behavior of these carriers. The rHDL carrier
systemwe developed was able to deliver siRNA specifically into hepatocytes while avoiding
the uptake by REM cells especially the Kupffer cells. With it’s low toxicity and off target
effect, it may be suitable to be developed as a hepatocyte targeting delivery system for
siRNA.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction average molecular weight of 13KD. A main obstacle for theirSmall interfering RNAs (siRNAs) are 21e23 nucleotide double-
strand RNA segments that could suppress gene expression by
activating RNA-induced silencing complex (RISC) and subse-
quently cleaving targeted mRNA [1,2]. It has been widely re-
ported that siRNAs have significant therapeutically potentials.
However, siRNAs are highly negatively charged with an, þ86 13501604118 (mobil
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univapplication is that siRNAs could be awfully unstable and
inefficient when entering target cells to exert the therapeutic
effects. Therefore there is an urgent need for siRNA delivery
systems to protect and direct siRNA molecules into the
diseased site and targeted cells [3e6].
There have a lot of efforts made in pursuing of safe and
efficient siRNA delivery systems. Delivery systems based one); fax: þ86 21 34204738.
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more versatile and practical, but the efficiencies had been in
general unsatisfactory. Recently there have been some pro-
gresses made in screening novel lipid structures for siRNA
delivery to the liver [7e10]. But there have been very limited
study investigating the detailed liver uptake mechanism
involved. Many studies had reported that after systemic
administration, most siRNA carriers could deposit massively
into the liver and sometimes the spleen [11e13]. But the liver
is a big and vital organ consisted of many cell types, including
parenchymal and non-parenchymal cells. In order to address
diseases involving the liver parenchymal, it would be impor-
tant to study the distribution pattern of different siRNA car-
riers among different cell types, and to optimize targeted
delivery to hepatocytes while avoiding the mononuclear
phagocyte cells.
In this study, we used an ApoA1 modified lipopolyplex
system as a model system to study the detailed distribution
and uptake patterns of fluorescence labeled siRNA in vivo
after iv administration. It’s prepared by complexing siRNA
with short PEI and then coating with EPC/Chol/ApoA1. It was
named rHDL-siRNA delivery system because the particle
morphology and surface properties resembled an HDL parti-
cle. We have shown in a previous study that such a carrier
system is almost non-toxic and can interact specifically with
hepatocytes and deliver siRNA into the cells [14]. In this study
we are very interested to examine its biodistribution after iv
injection and interaction with liver tissue and hepatocytes
in vivo. In addition, we alsowould like to compare such a rHDL
system with other delivery systems made from the classic
cationic lipid DOTAP and the commercial reagent
Invivofectamine2.0.2. Materials and methods
2.1. Materials
Branched polyethylenimine (PEI, MW 1800) and sodium
cholate were purchased from Alfa Aesar (MA, USA). Egg
phosphatidylcholine (EPC) and cholesterol were purchased
from NOF (Tokyo, Japan). DOTAP was purchased from Avanti
Polar Lipids (Alabama, USA). Recombinant human apolipo-
proteinA-Iwas expressed in Escherichia coli andpurified byHis-
Trapnickel affinity chromatographyas describedbyRyan et al.
[15]. Other materials were purchased from SigmaeAldrich
(St Louis, MO, USA).
Both fluorescence labeled and unlabeled siRNAs were
synthesized by Genepharm Co. (China). The siRNA targeting
the luciferase gene contained the anti-sense strand
50eUCGAAGUACUCAGCGUAAGdTdT-3’and sense strand 50-
CUUACGCUGAGUACUUCGAdTdT-30. Cy5 dye was labeled at
the 50-end of siLuc siRNA.
2.2. Preparation of rHDLs-siRNA
rHDLs-siRNA was prepared as described by Rui et al. [14]
Briefly, 60 mg of siRNA was dissolved in 214 ml of RNase-free
water. 16 ml of Branched PEI (1800 Da) (10mg/ml)was dissolved
in 284 ml RNase-free water. Then the siRNA solution wasadded to PEI solutions resulting in PEI/siRNA complexes. Li-
posomes with the lipid composition of EPC:cholesterol (20:1,
molar ratio) at a total lipid concentration of approximately
100 mM, were prepared using the thin film hydration method.
Then 130 ml of cholate solution (200 mg/ml in Tris buffer) and
1500 ml of apoA-I protein solution (7 mg/ml) were added to
liposome solutions to form mixed micelles containing lipid,
cholate and apoA1. The PEI/siRNA complex solution 600 ml was
then vortex-mixed with 1500 ml of the mixed micelles for
5 min. The final volume was adjusted to 6000 ml in 10 mM Tris
buffer. The mixture was incubated overnight at 4 C, and then
dialyzed against 2 L of Tris buffer, changing 3 times over 2
days.
2.3. Preparation of Invivofectamine 2.0-siRNA
The Invivofectamine-siRNA complexes were prepared based
on the protocol provided by invitrogen. Briefly, siRNA solution
was diluted using the Complexation Buffer to 1.5 mg/ml and
added directly to the Invivofectamine 2.0 reagent and vor-
texed immediately for 2e3 s. The mixture was incubated for
30min at 50 C and then loaded into the Float-A-Lyzer device
and dialyzed for 2 h in 1 L of PBS, pH 7.4, with gentle agitation.
2.4. Preparation of DOTAP-siRNA lipoplexes
DOTAP chloroform solution was dried into a lipid film and re-
suspended in 1 ml PBS. The DOTAP liposome solution was
mixedwith Cy5-siRNA at the N/P ratio of 8:1 and incubated for
half an hour before injection.
2.5. Physico-chemical characterization of the carriers
The siRNA loading efficiencies were evaluated by gel electro-
phoresis. The mean particles size and zeta potential of the
three carrier particles were measured by dynamic light scat-
tering using Zetasizer Nano-ZS90 (Malvern, UK).
2.6. Animal studies
The animal study protocol was approved by the institute’s
animal care and use committee. Female ICR mice (20e30 g)
were obtained from Shanghai B&K laboratory animal Corp.
Ltd. One group received the rHDLs-siRNA formulation at the
dose of 0.408 mg/kg by iv injection. They were sacrificed at
different time points (0.5, 2, 4, 24 h after the injection) for the
collection of liver for the immunohistochemistry study. The
Invivofectamine2.0-siRNA group received the iv injection at
0.547 mg/kg (body weight) dose. They were sacrificed at 0.5, 2,
4, 10 h for the collection of liver. The DOTAP-siRNA group
received the iv injection at 0.338mg/kg (bodyweight) dose and
they were sacrificed at 0.5, 2, 10 h for the collection of liver. In
addition, we also had a control group of mice received PBS
injections via the tail vein and liver were collected at 2 h post
dosing.
Before the collection of liver tissues, mice (n ¼ 3) were
deeply anesthetized with Chloral hydrate (40 mg/kg i.p.), and
perfused through the heart at a rate of 5ml/min using 20ml of
0.9% saline followed by 20 ml 4% paraformaldehyde. The liver
samples were then taken out and divided into four different
Fig. 1 e The siRNA loading efficiency of rHDLs-siRNA,
Invivofectamine2.0-siRNA and DOTAP-siRNA was
analyzed by gel electrophoresis. All samples were run on
1% agarose gel and stained with GelRed dye.
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usually use tissues from the left lateral lobe in our standard
procedure.2.7. Immunofluorescence study
The mouse liver tissue were sectioned and stained using
various antibodies to reveal the histology features and locate
the fluorescence labeled siRNA. The antibodies used included
anti-CD68 from AbD SeroTec (Raleigh, NC), anti-collagen IV
fromMillipore (Billerica,MA). In addition, the fluorescence dye
DAPI was used to stain the nuclei, and Phalloidin (Invitrogen,
Carlsbad, CA) was used to outline hepatocyte cell membrane
on the tissue sections. Specifically, 10 mm-thick frozen tissue
sections were cut using Cryostat (Leica CM1850), mounted on
Charged Slides (Premiere 9308W), and stored in a 80 C
freezer. Before staining, slides were allowed to air dry at room
temperature for 30 min. Tissue sections were washed with
1xPBS (PH 7.4, 3 5min), and incubated overnight at 4 C in 5%
serum from the species in which the secondary antibody was
generated. Afterward, the sections were stained with the
primary antibodies at the concentration of 10 mg/ml for 16 h atTable 1 e Characterization of rHDLs-siRNA-Cy5, Invivofectami
Test preparations Sizea (nm) Po
rHDLs-siRNA-Cy5 142.3  1.852
Invivo2.0-siRNA- Cy5 100.8  3.304
DOTAP-siRNA-Cy5 194.07  5.22
a Samples were diluted 1:50 with Tris buffer (pH8.0) or PBS buffer (PH7.4
b The polydispersity index of rHDLs-siRNA, Invivofectamine2.0-siRNA an
deviation of an underlying Gaussian size distribution.
c Samples were diluted 1:50 with Tris buffer (pH8.0), PBS buffer (PH7.4) f4 C washed again in PBS, and labeled with secondary anti-
bodies (Donkey anti-rat or rabbit IgG) conjugated with Alexa
488 (Invitrogen, Carlsbad, CA). Finally, all sections were
stained with DAPI to locate the nuclei, andmounted using the
aqueous mounting medium Prolong (Vector). The slides were
scanned using Confocal Microscope and images were
captured under three channels: DAPI for nuclei, Alex488 for
phalloidin-stained cell membrane or CD68, and Cy5 for siRNA.3. Results and discussion
3.1. Preparation and characterization of rHDLs-siRNA,
Invivofectamine2.0-siRNA and DOTAP-siRNA complexes
rHDLs-siRNA, Invivofectamine2.0-siRNA and DOTAP-siRNA
complexes were prepared as described. They were formu-
lated based on the optimization studies reported previously
[14,16,17] or as recommended by the supplier. The siRNA
encapsulation/complexation ratios in three formulationswere
all close to 100%because free siRNAbandwas no longer visible
in any of the formulations, as shown in Fig. 1. The size distri-
butions and Zeta potentials of the three types of complexes
were listed in Table 1. They all form small particles withmean
diameter at about 100 nm. The surface potentials were quite
different. The rHDLs-siRNA and Invivofectamine2.0-siRNA
particles were both slightly negative charged. The DOAP-
siRNA particles were highly positive charged.3.2. Histological and immunohistochemical analysis of
the liver tissues
In order to study the detailed intracellular distribution pat-
terns of the siRNA carrier, we first attempted to characterize
the major cell types using histology and immunohistochem-
ical methods. As shown in Fig. 2, mouse liver stained with a
standard hematoxylin and eosin (H&E) procedure reveal pat-
terns of cellular organization similar to what has been re-
ported [18e21].Majority of the cells can be identified as
hepatocytes, sinusoids (which contain endothelial linings),
Kupffer Cells [18e21].We applied immunofluorescent staining
of collagen IV to outline the sinusoidal endothelial cells.
Kupffer cells were identified using CD68 staining. Phalloidin
was used to outline cell membranes. It’s not specific to any
specific type, but hepatocytes can be easily identified
morphologically with features such as large single or double
nuclei with approximately 7 mm in diameter.ne2.0-siRNA-Cy5 and DOTAP-siRNA-Cy5.
lydispersity indexb (PdI) Zeta potentialc (mV)
0.200  0.017 4.99  1.13
0.289  0.031 5.70  1.20
0.267  0.006 18.57  2.17
) for DLS measurement.
d DOTAP-siRNA correspond to the square of the normalized standard
or zeta potential measurement.
Fig. 2 e H&E staining and immunofluorescence staining Photomicrographs of mouse liver tissue. Bright field images
showing central venule (A, B) and Kupffer cells (C, D). (E) Nuclei outlined with DAPI. (F) Phalloidin outlined liver cells (green)
(G) CD68-stained Kupffer cells. (H) Overlay images for phalloidin outlined liver cells (green), CD68-stained Kupffer cells and
nuclei (DAPI, blue).
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the liver and their uptake by hepatocytes
The intracellular distribution and uptakemechanismof rHDLs
in the liver was investigated by confocal microscopy. Cy5
labeled rHDL-siRNAwas injected via tail vein of ICRmice at the
dose of 0.408 mg/kg body weight. Tissue sections from livers
collectedat different timepoints after injectionwere analyzed.
As shown in Fig. 3, the amount of visible red cy5 signals were
quite rare at 0.5 h after injection (Figs. 2E and 3A) but they
increased to a significant number after 2 h (Figs. 2F and 3B).
Interestingly, these positive signals are clearly all insideFig. 3 e rHDLs-siRNA-Cy5 biodistribution in mouse liver at 0.5 h
and counterstained with DAPI (blue). (AeH) Overlaid images of C
(DAPI blue) for the time points. Cy5esiRNA distributed in the liv
24 h, and (H) PBS control.hepatocytes, indicating a specific uptake mechanism by he-
patocytes. The signals became diffused and eventually died
downafter 4 h and 24h (Figs. 2D and 3C, G). These observations
agreed very well with our earlier report describing the hepa-
tocyte uptake of rHDLs in vitro. The ApoA1 and surface prop-
erties resembling the natural HDL particles enabled a specific
uptake mechanism of the rHDL-siRNA particles by hepato-
cytes. They were taken up into closed compartments (endo-
some or early lysosome) and then released into the cytoplasm
probably based on the PEI photon sponge effect. However,
compared with the in vitro data [14], the amount of fluores-
cence signals inside hepatocytesweremuchweaker. Thismay, 2 h, 4 h, 24 h Sections were stained with phalloidin (green)
y5 (red) and phalloidin outlined liver cells (green) and nuclei
er is time dependent. (A, E) 30 min, (B, F) 2 h, (C, G) 4 h, (D)
Fig. 4 e Invivofectamine2.0-siRNAbiodistribution in mouse liver 0.5, 2 h, 4 h, 10 h post injection Sections were stained with
phalloidin (green) and counterstained with DAPI (blue). (AeH) Overlaid images of Cy5 (red) and phalloidin outlined liver cells
(green) and nuclei (DAPI blue) for the time points. (A, E) 30 min, (B, F) 2 h, (C, G) 4 h, (D) 10 h, and (H) PBS control.
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blood so that there were only limited numbers available in the
liver. Therefore the siRNA efficiency (activity per dose) was
much lower in vivo than what we could obtain in vitro. But a
clearadvantageof the rHDL-siRNAformulation is itsminimum
toxicity [14], so it is possible to increase the dose to improve
efficacy. In this studywealso showed that rHDLswere takenup
only by hepatocytes with almost none in Kupffer cells and
likes. It’s also important because there had always been a
concern for off target effect of siRNAmediatedbyKupffer cells.
For comparison, we also examined the distribution and
uptake patterns of the Invivofectamine2.0-siRNA andFig. 5 e DOTAP-siRNA biodistribution in mouse liver Sections w
DAPI (blue). (AeF) Overlaid images of Cy5 (red) and phalloidin ou
points. (A, D) 30 min, (B, E) 2 h, (C) 10 h, and (F) PBS control.DOTAP/siRNA complexes. Their time course pictures were
shown in Figs. 4 and 5 respectively. The cy5 fluorescence
distribution patterns were completely different. The
Invivofectamine2.0-siRNA particles showed up quickly in the
liver but were mostly outside of the cells binding to the cell
membrane within half hour of the injection (Figs. 4A and E).
They were then taken up into intracellular compartments at
around 2e4 h after injection (Fig. 4B, C, F and G) and gradually
diffused out after 10 h (Fig. 4D). The DOTAP-siRNA particles,
however, were seen only in sinusoids and colocalized with
CD68 labeled Kupffer cells (Fig. 5AeE). These observations
agreed with most of the literature describing the distributionere stained with phalloidin (green) and counterstained with
tlined liver cells (green) and nuclei (DAPI blue) for the time
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It was proposed that Invivofectamine2.0-siRNA particles
would interact with LDLs during circulation and bind to he-
patocytes mediated by the LDL receptor [23,24]. On the other
hand, DOTAP-siRNA complexes, being positively charged,
would interact with the opsonins and then be taken up by
Kupffer cells. They represent two distinctive pathways that
were both different from the rHDL-siRNA uptake mechanism
we described in this study.
The most logical and feasible way to introduce siRNA car-
riers into the liver cells is through intravenous injection. The
injected particles enter the liver from portal vein to sinusoids
and exit through the central veins. Particles with sizes of
about 150 nm could diffuse out of the liver sinusoidal endo-
thelial lining via the fenestrae and come into direct contact
with hepatocytes [25e27]. Specific mechanisms are required
for the particles to bind to hepatocytes and initiate the
endocytosis process.4. Conclusion
In summary, we’ve shown that rHDL-siRNA carriers could be
used as a prospective delivery system for safe and efficient
delivery of siRNA to hepatocytes in vivo. Because the common
obstacle for current siRNA delivery strategies is the accumu-
lation in organs of RES systems, the unique properties of the
rHDL nanoparticle make it a potential vector for hepatocyte-
specific delivery of siRNA.
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